Skip to main content
Log in

Wie viel Staging braucht der Mensch?

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Das gegenwärtige Staging- und TNM-System, das zuletzt 1997 revidiert wurde, wartet aufgrund sich verbessernder Behandlungsprognosen für einzelne Patientengruppen als auch einer immer besseren Kenntnis pathologisch-anatomischer Prognosefaktoren beim Bronchialkarzinom auf eine weitere Erneuerung. Insbesondere lymphogen fortgeschrittene Tumoren, T4- und M1-Situationen sind bis dato teilweise nicht differenziert genug erfasst, was für eine kleine, aber bedeutsame Patientengruppe an der Grenze zwischen kurativer und palliativer Therapie unzureichend erscheint. Maßgeblich für das individuelle Staging sollte ein zurückhaltender, abgestufter Ansatz sein, der stets die therapeutischen Konsequenzen im Auge hat. Innovative Stagingverfahren wie die Positronenemissionstomographie müssen angesichts überwiegend palliativer Therapieansätze auf eine breitere klinische Erfordernis hin als auch im Kosten-Nutzen-Vergleich noch differenzierter bewertet werden als bisher.

Abstract

The present staging and TNM system for lung cancer is under debate. After revision in 1997, the prognoses of subgroups of patients have improved due to advanced therapeutic concepts, and a deeper insight has been attained into prognostic factors based on pathological anatomy. Especially tumours with lymphogenic spread, T4 and M1 situations are described insufficiently, which could be meaningful for a small but important subgroup of patients who may or may not profit from a curative approach. The individual staging should be based on a sparing stepwise algorithm always keeping the therapeutic consequences in mind. Innovative staging procedures such as positron emission tomography require further evaluation on their use for the large group of palliatively treated patients, as well as cost-benefit aspects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Batevik R, Grong K, Segadal L, Stangeland L (2005) The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer 47:173–181

    Article  Google Scholar 

  2. Berghmans T, Lafitte JJ, Thiriaux J et al. (2004) Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. Lung Cancer 45:339–348

    Article  Google Scholar 

  3. Egermann U, Jaeggi K, Habicht JM et al. (2002) Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients? Eur Respir J 19:464–468

    Article  Google Scholar 

  4. Furak J, Trojan I, Szoke T et al. (2005) Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg 79:241–247

    Article  Google Scholar 

  5. Gdeedo A, Van Schil P, Corthouts B et al. (1997) Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 10:1547–1551

    Article  Google Scholar 

  6. Gu CD, Osaki T, Oyama T et al. (2002) Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and survival. Ann Surg 235:133–139

    Article  PubMed  Google Scholar 

  7. Herth FJ (2004) Mediastinal staging—the role of endobronchial and endo-oesophageal sonographic guided needle aspiration. Lung Cancer 45 [Suppl 2]:S63–S67

    Google Scholar 

  8. Huber RM, Stratakis DF (2004) Molecular oncology—perspectives in lung cancer. Lung Cancer 45 [Suppl 2]:S209–S213

    Google Scholar 

  9. Kim JH, Kim YT, Lim HK et al. (2003) Management for chest wall implantation of non-small cell lung cancer after fine-needle aspiration biopsy. Eur J Cardiothorac Surg 23:828–832

    Article  Google Scholar 

  10. Le Chevalier T, for the IALT Investigators (2003) Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:2

    Google Scholar 

  11. Mountain CF (1994) Surgery for stage IIIa-N2 non-small cell lung cancer. Cancer 73:2589–2598

    Google Scholar 

  12. Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111:1710–1717

    CAS  PubMed  Google Scholar 

  13. Naruke T, Tsuchiya R, Kondo H, Asamura H (2001) Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 71:1759–1764

    Article  Google Scholar 

  14. Okada M, Tsubota N, Yoshimura M et al. (1999) Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg 68:326–330

    Article  Google Scholar 

  15. Osaki T, Sugio K, Hanagiri T et al. (2003) Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg 75:1745–1751

    Article  Google Scholar 

  16. Passlick B, Kubuschock B, Sienel W et al. (2002) Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases—results of a preliminary study. Eur J Cardiothorac Surg 21:520–526

    Article  Google Scholar 

  17. Porte H, Siat J, Guibert B et al. (2001) Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann Thorac Surg 71:981–985

    Article  Google Scholar 

  18. Thomas M, Gatzemeier U, Goerg R et al. (2000) Empfehlungen zur Diagnostik des Bronchialkarzinoms. Pneumologie 54:361–371

    Article  Google Scholar 

  19. van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374–379

    Article  Google Scholar 

  20. Vansteenkiste JF, Dooms CA (2004) The role of positron emission tomography with18F-2-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir Mon 30:245–264

    Google Scholar 

  21. Verschakelen JA, de Wewer W, Bogaert J, Stroobants S (2004) Imaging: staging of lung cancer. Eur Respir Mon 30:214–244

    Google Scholar 

  22. Walsh GL, O’Connor M, Willis KM et al. (1995) Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 60:1563–1570

    Article  Google Scholar 

  23. Yeow KM, Su IH, Pan KT et al. (2004) Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest 126:748–754

    Article  Google Scholar 

  24. Yoshino I, Nakanishi R, Osaki T et al. (1997) Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis. Ann Thorac Surg 64:809–813

    Article  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N. Schönfeld.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schönfeld, N. Wie viel Staging braucht der Mensch?. Pneumologe 2, 118–122 (2005). https://doi.org/10.1007/s10405-005-0031-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-005-0031-6

Schlüsselwörter

Keywords

Navigation